Screening For Peripheral Sensory Neuropathy In a Tunisian Population of Patients With Diabetes

##plugins.themes.bootstrap3.article.main##

  •   Chaima Jemai

  •   Sinène EL Frigui

  •   Faika Ben Mami

Abstract

Aims: Diabetes is a public health problem in the world. Its prevalence as well as that of degenerative complications, such as peripheral sensory neuropathy, are high. Our study was aimed at determining the prevalence of peripheral sensory neuropathy in a Tunisian population of patients with diabetes and  identifying its associated risk factors.


Methods: It was a descriptive prospective study conducted in department C of Diabetology and Nutrition of the National Institute of Nutrition of Tunis (September 2019). 100 patients with diabetes have been enrolled. Peripheral sensitive neuropathy was screened by the 10 g monofilament test.


Results: The mean age was 54±12.9 years, The sex ratio was 0.78. Active smoking was 35% common. Diabetes was type 2 in the majority of cases (78%). The average duration of diabetes was 13.62±6.29 years. 78% of the population has been unbalanced. The prevalence of peripheral sensory neuropathy was 41%. It was significantly associated with diabetes duration (p<10-3), smoking (p=0.007) and diabetic retinopathy (p=0.032). Unbalnaced diabetes was not significantly associated with PSN (p=0,09).


Conclusion: Screening for peripheral sensory neuropathy is compulsory because it can be asymptomatic and revealed at the stage of complications. Risk factors should be known and screened. This contribute in optimizing patients managing.


Keywords: Diabetes, Diabetic retinopathy, Peripheral sensory neuropathy, Smoking, 10 g monofilament test

References

Bonita R, WInkelmann R, Douglas KA, Courten M, McQueen DV, Puska P. The WHO stepwise approach to surveillance (STEPS) of non communicable disease risk factors. Bihavioral Risk Factor Surveillence. New York: Kluwer academic/Plenum publishers.2003; 9-22.

Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. International Journal for Equity in Health. 2005; 4:2.

Fédération international de diabète. Atlas de diabète de l'IDF, Sixième édition, 2013.

Wild S. Global prevalence of diabetes-estimated for the year 2000 and projections for 2030. Diabetes care, 2007; 20: 1183-93.

2-Bakris G, Blonde L, Boulton AJM, D'Alessio D, Greene EL, Hood KK et al. Diabetes care. 2019 ;42 (Suppl 1).

American Diabetes Association. Position Statement. Preventive foot care in diabetes. Diabetes Care. 2004; 27 (Suppl 1) :63-4.

-The diabetec control and complications trail research Group. N Engl J Med. 1993; 329-977.

-Martin CL, Albers JW,Pop-Busui R; DCCT/EDIC Research group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes care. 2014; 37: 31-8.

Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clinic proceedings. 2006 ;81(Suppl 4) :3-11.

Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clinical Therapeutics. 2018 ;40(6) :828-49.

Reilhers L, Buvry S, Goletto M, Schuldiner S, Richard JL. OP3 Dépistage du risque podologique: seuil de perception vibratoire ou monofilament?. Diabetes metab. 2011 ;38: 125.

Kamel M. Prévalence élevée de la neuropathie périphérique dès le stade de prédiabète. Médecine des maladies Métaboliques. 2016; 10.

Said G, Goulon-Goeau C, Slama G, Tchobroutsky G. Sever early-onset polyneuropathy in insulin-dependent diabetes mellitus.A clinical and pathologucal study. N Engl J Med. 1992; 326: 1257-63.

Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Annals of Saudi medicine. 2007 ;27(1) :25–31.

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996 ;39(11) :1377–84.

Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989 ;38(11) :1456–61.

Kiani J, Moghimbeigi A, Azizkhani H, Kosarifard S. The prevalence and associated risk factors of peripheral diabetic neuropathy in Hamedan, Iran. Archives of Iranian medicine. 2013 ;16(1) :17–9.

Nie C, Bao HP. Analysis of the related risk factors of diabetic peripheral neuropathy. Chinese journal of experimental and clinical virology. 2012 ;26(6) :467–9.

Yang CP, Lin CC, Li CI, Liu CS, Lin WY, Hwang KL, et al. Cardiovascular Risk Factors Increase the Risks of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes Mellitus: The Taiwan Diabetes Study. Medicine. 2015 ;94(42) :e1783 10.1097/MD.0000000000001783.

Chen L, Zheng F, Li H. A change of serum cystatin C in diabetic peripheral neuropathy in type 2 diabetic patients and its clinical significance. Chinese Journal of Diabetes. 2014 ;22(8) :700–3.

Wei W, Wang Z, Zhou l, Zhao S, Mao H. Risk factors analysis of diabetic peripheral neuropathy in patients with type 2 diabetes. Hainan Medical Journal. 2017 ;28(20) :3379–81.

Chen X, Bi Y, Hu Y, Tong G, Zhu D. Prevalence and risk factors of diabetic peripheral neuropathy. Journal of Medical Postgraduates. 2011 ;24(10) :1035–8.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

How to Cite
Jemai, C., EL Frigui, S., & Ben Mami, F. (2020). Screening For Peripheral Sensory Neuropathy In a Tunisian Population of Patients With Diabetes. European Journal of Medical and Health Sciences, 2(4). https://doi.org/10.24018/ejmed.2020.2.4.382

Most read articles by the same author(s)